Commission Implementing Regulation (EU) No 84/2012
of 1 February 2012
amending the Annex to Regulation (EU) No 37/2010 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin, as regards the substance phenoxymethylpenicillin
(Text with EEA relevance)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to the opinion of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,
Whereas:
The maximum residue limit for pharmacologically active substances intended for use in the Union in veterinary medicinal products for food-producing animals or in biocidal products used in animal husbandry should be established in accordance with Regulation (EC) No 470/2009.
Phenoxymethylpenicillin is currently included in Table 1 of the Annex to Regulation (EU) No 37/2010 as an allowed substance, for porcine species, applicable to muscle, liver and kidney and for poultry species, applicable to muscle, skin and fat, liver and kidney, excluding animals from which eggs are produced for human consumption.
An application for the extension of the existing entry for phenoxymethylpenicillin to include eggs for poultry species has been submitted to the European Medicines Agency.
The Committee for Medicinal Products for Veterinary Use has recommended establishing a maximum residue limit (hereinafter ‘MRL’) for phenoxymethylpenicillin for porcine species, applicable to muscle, liver and kidney and for poultry species, applicable to muscle, skin and fat, liver, kidney and eggs.
The entry for phenoxymethylpenicillin in Table 1 of the Annex to Regulation (EU) No 37/2010 should therefore be amended to include the MRL for eggs for poultry species.
It is appropriate to provide for a reasonable period of time for the stakeholders concerned to take measures that may be required to comply with the newly set MRL.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,
HAS ADOPTED THIS REGULATION: